PTCT Stock Analysis: PTC Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.380m USD | 12M Return: -12% | US69366J2006 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 61.4M
Qual. Beats: 0
Rev. Trend: 31.0%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
PTC Therapeutics, Inc. is a biopharmaceutical company founded in 1998 and headquartered in Warren, New Jersey, that develops and commercializes treatments for rare diseases affecting children and adults, primarily in the U.S. and select international markets. Its marketed portfolio includes Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza (brand name Kebilidi in the U.S.) for AADC deficiency, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy, the last of which is developed through a collaboration with Roche. The company is also advancing a pipeline that features Sepiapterin for phenylketonuria, PTC518 for Huntingtons disease under a collaboration with Novartis, and vatiquinone for Friedreichs ataxia, among other earlier-stage programs.
The company distributes its products through third-party distributors and maintains collaborations with several partners, including Roche, the SMA Foundation, Akcea Therapeutics, and Shiratori Pharmaceutical. As a rare disease-focused biotechnology firm, PTC Therapeutics operates within a sector characterized by lengthy drug development cycles, heavy reliance on regulatory designations such as orphan drug exclusivity, and revenue concentrated in a small number of specialized products.
- Translarna CHMP decision drives DMD franchise revenue
- Evrysdi royalties from Roche partnership grow SMA revenue
- PTC518 Huntingtons Phase 2 data key catalyst for Novartis collaboration
| Net Income: -106.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -22.39 > 1.0 |
| NWC/Revenue: 152.5% < 20% (prev 64.16%; Δ 88.29% < -1%) |
| CFO/TA 0.00 > 3% & CFO 10.5m > Net Income -106.0m |
| Net Debt (1.70b) to EBITDA (174.5m): 9.74 < 3 |
| Current Ratio: 3.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (83.5m) vs 12m ago -4.18% < -2% |
| Gross Margin: 92.39% > 18% (prev 91.20%; Δ 1.19% > 0.5%) |
| Asset Turnover: 39.50% > 50% (prev 67.30%; Δ -27.80% > 0%) |
| Interest Coverage Ratio: 0.57 > 6 (EBIT TTM 113.5m / Interest Expense TTM 198.6m) |
| A: 0.55 (Total Current Assets 2.54b - Total Current Liabilities 776.1m) / Total Assets 3.21b |
| B: -0.92 (Retained Earnings -2.94b / Total Assets 3.21b) |
| C: 0.04 (EBIT TTM 113.5m / Avg Total Assets 2.93b) |
| D: -0.06 (Book Value of Equity -191.2m / Total Liabilities 3.40b) |
| Altman-Z'' = 0.82 = B |
| DSRI: 1.80 (Receivables 238.1m/203.1m, Revenue 1.16b/1.78b) |
| GMI: 0.99 (GM 91.20% / 92.39%) |
| AQI: 0.91 (AQ_t 0.17 / AQ_t-1 0.19) |
| SGI: 0.65 (Revenue 1.16b / 1.78b) |
| TATA: -0.04 (NI -106.0m - CFO 10.5m) / TA 3.21b) |
| Beneish M = -2.69 (Cap -4..+1) = A |
As of October 31, 2026, the stock is trading at USD 59.97 with a total of 2,349,386 shares traded. Over the past week, the price has changed by -1.02%, over one month by -7.68%, over three months by -20.59% and over the past year by -11.95%.
Current recommended Stop Loss: 57.50 (which is 4.1% or 1.2 ATR below the current price).
PTC Therapeutics has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy PTCT.
- StrongBuy: 9
- Buy: 4
- Hold: 2
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 97.8 | 63.1% |
P/E Forward = 22.9885
P/S = 5.3332
P/B = 1743.2734
P/EG = 0.81
Revenue TTM = 1.16b USD
EBIT TTM = 113.5m USD
EBITDA TTM = 174.5m USD
Long Term Debt = 2.03b USD (from longTermDebt, last fiscal year)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 2.15b USD (corrected: LT Debt 2.03b + ST Debt 14.2m) + Leases 105.5m
Net Debt = 1.70b USD (calculated: Debt 2.15b - CCE 444.8m)
Enterprise Value = 7.08b USD (5.38b + Debt 2.15b - CCE 444.8m)
Interest Coverage Ratio = 0.57 (Ebit TTM 113.5m / Interest Expense TTM 198.6m)
EV/FCF = -1000.0x (Enterprise Value 7.08b / FCF TTM -4.35m)
FCF Yield = -0.06% (FCF TTM -4.35m / Enterprise Value 7.08b)
FCF Margin = -0.38% (FCF TTM -4.35m / Revenue TTM 1.16b)
Net Margin = -9.17% (Net Income TTM -106.0m / Revenue TTM 1.16b)
Gross Margin = 92.39% ((Revenue TTM 1.16b - Cost of Revenue TTM 87.9m) / Revenue TTM)
Gross Margin QoQ = 93.39% (prev 94.47%)
Tobins Q-Ratio = 2.21 (Enterprise Value 7.08b / Total Assets 3.21b)
Interest Expense / Debt = 9.26% (Interest Expense 198.6m / Debt 2.15b)
Taxrate = 2.01% (14.0m / 696.6m)
NOPAT = 111.2m (EBIT 113.5m * (1 - 2.01%))
Current Ratio = 3.10 (Total Current Assets 2.54b / Total Current Liabilities 817.7m)
Debt / Equity = -11.22 (negative equity) (Debt 2.15b / totalStockholderEquity, last quarter -191.2m)
Debt / EBITDA = 9.74 (Net Debt 1.70b / EBITDA 174.5m)
Debt / FCF = -390.6 (out of range, set to none) (Net Debt 1.70b / FCF TTM -4.35m)
Total Stockholder Equity = -185.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -3.62% (Net Income -106.0m / Total Assets 3.21b)
RoE = 57.10% (negative equity) (Net Income TTM -106.0m / Total Stockholder Equity -185.6m)
RoCE = 6.17% (EBIT 113.5m / Capital Employed (Equity -185.6m + L.T.Debt 2.03b))
RoIC = 4.66% (NOPAT 111.2m / Invested Capital 2.39b)
WACC = 7.58% (E(5.38b)/V(7.52b) * Re(6.98%) + D(2.15b)/V(7.52b) * Rd(9.26%) * (1-Tc(0.02)))
Discount Rate = 6.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 65.53 | Cagr: 3.82%
[DCF] Fair Price = unknown (Cash Flow -4.35m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.12 | # QB: 0
Revenue Correlation: 31.05 | Revenue CAGR: 11.98% | SUE: 0.18 | # QB: 0
EPS current Year (2026-12-31): EPS=1.52 | Chg30d=-11.30% | Revisions=+0% | GrowthEPS=-80.1% | GrowthRev=-27.3%
EPS next Year (2027-12-31): EPS=2.37 | Chg30d=-11.46% | Revisions=+0% | GrowthEPS=+56.3% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: +0% (up=2, down=2)